The latest trading day saw Pfizer (PFE) settling at $25.60, representing a -0.43% change from its previous close.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Sponsored by the Indian Council of Social Science Research (ICSSR), the seminar served as a platform for experts, researchers, and students to discuss the role of artificial intelligence (AI) in ...

Núñez Feijóo, the leader of the Spanish People's Party (Partido Popular/EPP), the main opposition force in Parliament, met with Sánchez (PSOE/S&D) for talks on how the government intends to reach its ...

A 400-home neighbourhood at Hazelhurst Farm in Worsley, a site allocated in Greater Manchester’s Places for Everyone development plan, will go to committee for a decision next week.

This article has been corrected to reflect that the senators asked UpScriptHealth to respond. In August 2024, Pfizer Inc ...

In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total ...

Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

Pfizer has terminated a Phase I trial of its investigational STING therapy in advanced solid tumors, according to an update ...

Knight-Swift Transportation Holdings Inc. (NYSE: KNX) (the "Company" or "Knight-Swift") announced today that Douglas Col has joined Knight-Swift's Board of Directors (the "Board") effective March 13, ...

The Hopkins School Board heard from the district's special education department at its latest work session, learning its day-to-day functions and how it has been chronically plagued by budget dilemmas ...